@aditharun_ the analysts/ banks that publish research want companies to use them for financings or M&A. Optimistic valuations helps keep management happy and more likely to use the bank
@A_May_MD@Sanctuary_Bio@Getoutofmyway1 My thought was that while CM drives costs like hospitalizations and acute cardiac interventions, the main FA cost driver comes from neuro disability and long term care needs. But the former is still pretty costly, to your point
@A_May_MD@Sanctuary_Bio@Getoutofmyway1 But is LXEO’s cardiac frataxin really any better? Payers care about costs of care/ disability. CM drives mortality, not so much disability (driven by neuro)